ARAY - Accuray Incorporated
After hours:
| Previous Close | 3.5800 |
| Open | 3.5400 |
| Bid | 3.5000 x 1200 |
| Ask | 3.7900 x 900 |
| Day's Range | 3.5400 - 3.6500 |
| 52 Week Range | 1.7000 - 3.8600 |
| Volume | |
| Avg. Volume | 382,669 |
| Market Cap | 347.579M |
| Beta (5Y Monthly) | 1.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?
Investors are optimistic about Accuray's (ARAY) solid product portfolio.
- Simply Wall St.
Investors in Accuray (NASDAQ:ARAY) have seen decent returns of 73% over the past three years
By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...
- Motley Fool
Why Shares of Accuray Rose Thursday
Shares of Accuray (NASDAQ: ARAY) were up by more than 15% early Thursday afternoon after the healthcare company released its fiscal 2023 third-quarter earnings Wednesday afternoon. The radiation oncology device specialist makes the CyberKnife and Tomo Therapy systems, which deliver radiosurgery, stereotactic body radiation therapy (SBRT), intensity-modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The fiscal quarter, which ended March 31, was the company's first in the black since its fiscal 2022 second quarter (i.e., calendar Q4 2021).
- Zacks
Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates
Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.
- Zacks
Accuray (ARAY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- Zacks
Accuray (ARAY) Q3 Earnings and Revenues Beat Estimates
Accuray (ARAY) delivered earnings and revenue surprises of 200% and 6.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
MedTech Stocks' Q1 Earnings Due on Apr 26: MMSI, CNMD & More
Medical Device players are expected to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MMSI, CNMD, NVRO and ARAY are likely to have performed this time.
- Simply Wall St.
Accuray Incorporated's (NASDAQ:ARAY) Low P/S No Reason For Excitement
You may think that with a price-to-sales (or "P/S") ratio of 0.7x Accuray Incorporated ( NASDAQ:ARAY ) is definitely a...
- Simply Wall St.
With 53% institutional ownership, Accuray Incorporated (NASDAQ:ARAY) is a favorite amongst the big guns
Key Insights Given the large stake in the stock by institutions, Accuray's stock price might be vulnerable to their...
- Zacks
Here's Why You Should Retain Accuray (ARAY) Stock for Now
Investors continue to be optimistic about Accuray (ARAY) owing to strong demand for its products.
- Simply Wall St.
Accuray's (NASDAQ:ARAY) Returns On Capital Are Heading Higher
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'll want to see a proven...
- Motley Fool
Why Shares of Accuray Jumped Thursday
Shares of Accuray (NASDAQ: ARAY) were up as much as 17.6% on Thursday. The medical instruments maker, which specializes in radiation oncology machines, released its fiscal 2023 second-quarter earnings report late Wednesday. In the second-quarter report, CEO Suzanne Winter said the company set a record with 29 new systems delivered.
- Zacks
Accuray (ARAY) Q2 Earnings and Revenues Top Estimates
Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance.
- Zacks
Accuray (ARAY) Reports Q2 Loss, Tops Revenue Estimates
Accuray (ARAY) delivered earnings and revenue surprises of 33.33% and 7.98%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Accuray (NASDAQ:ARAY) investors are sitting on a loss of 60% if they invested a year ago
The nature of investing is that you win some, and you lose some. Anyone who held Accuray Incorporated ( NASDAQ:ARAY...
- Simply Wall St.
Accuray First Quarter 2023 Earnings: Misses Expectations
Accuray ( NASDAQ:ARAY ) First Quarter 2023 Results Key Financial Results Revenue: US$96.5m (down 10% from 1Q 2022). Net...
- Zacks
Accuray's (ARAY) Q1 Earnings and Revenues Lag Estimates
Despite solid product demand, Accuray (ARAY) reports an overall soft Q1 performance.
- Zacks
Accuray (ARAY) Reports Q1 Loss, Misses Revenue Estimates
Accuray (ARAY) delivered earnings and revenue surprises of -500% and 8.20%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
McKesson (MCK) Q2 Earnings Miss Estimates, Revenues Rise Y/Y
McKesson's (MCK) fiscal second-quarter 2023 results benefit from segmental growth.
- Zacks
Ecolab (ECL) Q3 Earnings & Revenues Miss Mark, Margins Down
Ecolab's (ECL) robust performance across all its segments drives its Q3 sales, despite business challenges.
- Zacks
DexCom (DXCM) Q3 Earnings Beat Estimates, Guidance Revised
DexCom's (DXCM) third-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
- Zacks
Baxter (BAX) Q3 Earnings Meet Estimates, Hilrom Adds $735 M
Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
- Zacks
Integra's (IART) Q3 Earnings Top, Gross Margin Declines
Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.
- Zacks
Align Technology (ALGN) Q3 Earnings Lag Estimates, Margins Drop
The volatility surrounding inflationary pressure, weaker consumer confidence and the lingering impacts of COVID-19 shutdowns continue to pose challenges for Align Technology (ALGN).
